Mr. Thomas Vecchiolla announced that he will be resigning as a director of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) effective January 1, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
David LaPre was appointed as Director at Calidi Biotherapeutics, Inc..
Action
appointed
Role
Director
Exact text from the filing
the Board appointed Mr. David LaPre as a director to fill the vacancy in connection with Mr. Vecchiolla’s departure, effective January 1, 2024.
Thomas Vecchiolla resigned as Director at Calidi Biotherapeutics, Inc..
Action
resigned
Role
Director
Exact text from the filing
Mr. Thomas Vecchiolla announced that he will be resigning as a director of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) effective January 1, 2024.
Material AgreementsSEC 8-K Item 1.01/1.02confidence 0.9
Calidi Biotherapeutics, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. valued at up to $25,000,000 (effective 2023-12-10).
Action
entry
Agreement
equity purchase
Counterparty
YA II PN, Ltd.
Value
up to $25,000,000
Effective
2023-12-10
Exact text from the filing
On December 10, 2023, Calidi Biotherapeutics, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd., a Cayman Island exempt limited partnership (“Yorkville”). Pursuant to the SEPA, the Company will have the right, but not the obligation, to sell to Yorkville up to $25,000,000 of its shares of Common Stock, par value $0.0001 per share (the “Common Stock”), at the Company’s request any time during the 36 months following the execution of the SEPA.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.